Company registration number 15610529 (England and Wales)
MEDIPHARM PRO LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 SEPTEMBER 2025
PAGES FOR FILING WITH REGISTRAR
MEDIPHARM PRO LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 4
MEDIPHARM PRO LIMITED
BALANCE SHEET
AS AT
30 SEPTEMBER 2025
30 September 2025
- 1 -
2025
Notes
£
£
Fixed assets
Investments
3
2,365,355
Current assets
Debtors
4
47,181
Cash at bank and in hand
37,089
84,270
Creditors: amounts falling due within one year
5
(929,482)
Net current liabilities
(845,212)
Total assets less current liabilities
1,520,143
Creditors: amounts falling due after more than one year
6
(1,512,786)
Net assets
7,357
Capital and reserves
Called up share capital
2
Profit and loss reserves
7,355
Total equity
7,357

For the financial period ended 30 September 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the period in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 5 March 2026 and are signed on its behalf by:
Mr RJ Dodhia
Director
Company registration number 15610529 (England and Wales)
MEDIPHARM PRO LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 SEPTEMBER 2025
- 2 -
1
Accounting policies
Company information

Medipharm Pro Limited is a private company limited by shares incorporated in England and Wales. The registered office is Elthorne Gate, 64 High Street, Pinner, Middlesex, HA5 5QA.

1.1
Reporting period

These are the first set of financial statements prepared by the company after the incorporation. Therefore, there are no comparatives included and the financial statements are prepared for the period of 17 months and 29 days.

1.2
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

Preparation of consolidated financial statements

The financial statements contain information about Medipharm Pro Limited as an individual Company and do not contain consolidated financial information as the parent of a group. The Company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

1.3
Fixed asset investments

Investments in subsidiary undertakings are recognised at cost.

1.4
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

MEDIPHARM PRO LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 30 SEPTEMBER 2025
1
Accounting policies
(Continued)
- 3 -
1.5

Related party exemption

The company has taken advantage of the exemption, under the terms of Financial Reporting Standard 102,' The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

2
Employees

The average monthly number of persons (including directors) employed by the company during the period was:

2025
Number
Total
2
3
Fixed asset investments
2025
£
Shares in group undertakings and participating interests
2,365,355
Movements in fixed asset investments
Shares in subsidiaries
£
Cost or valuation
At 2 April 2024
-
Additions
2,365,355
At 30 September 2025
2,365,355
Carrying amount
At 30 September 2025
2,365,355
4
Debtors
2025
Amounts falling due within one year:
£
Amounts owed by group undertakings
47,181
MEDIPHARM PRO LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 30 SEPTEMBER 2025
- 4 -
5
Creditors: amounts falling due within one year
2025
£
Bank loans
129,485
Amounts owed to group undertakings
799,997
929,482
6
Creditors: amounts falling due after more than one year
2025
£
Bank loans and overdrafts
1,512,786

The bank loans falling due within one year and more than one year are secured by:

(a) first fixed charges over the Company’s freehold and leasehold properties, plant and machinery, book debts, receivables, and intellectual property;

(b) a first floating charge over the Company’s undertaking and all other present and future assets.

7
PARENT UNDERTAKING

The ultimate parent compan ies are Mediken Li mited and KSMP Limited, which are incorporated in England and Wales.

2025-09-30 2024-04-02 false false false 05 March 2026 CCH Software CCH Accounts Production 2025.300 No description of principal activity Mr SK Patel Mr RJ Dodhia 15610529 2024-04-02 2025-09-30 15610529 2025-09-30 15610529 core:WithinOneYear 2025-09-30 15610529 core:AfterOneYear 2025-09-30 15610529 core:CurrentFinancialInstruments 2025-09-30 15610529 core:ShareCapital 2025-09-30 15610529 core:RetainedEarningsAccumulatedLosses 2025-09-30 15610529 bus:Director2 2024-04-02 2025-09-30 15610529 core:Non-currentFinancialInstruments 2025-09-30 15610529 bus:PrivateLimitedCompanyLtd 2024-04-02 2025-09-30 15610529 bus:SmallCompaniesRegimeForAccounts 2024-04-02 2025-09-30 15610529 bus:FRS102 2024-04-02 2025-09-30 15610529 bus:AuditExemptWithAccountantsReport 2024-04-02 2025-09-30 15610529 bus:Director1 2024-04-02 2025-09-30 15610529 bus:FullAccounts 2024-04-02 2025-09-30 xbrli:pure xbrli:shares iso4217:GBP